# Embecta Corp. (EMBC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $5.80, market value $329 million.

## Valuation
- **P/E (trailing): 3.9×** (5-yr avg 8.9×, 3-yr avg 9.7×). Embecta Corp. trades at 3.9× trailing earnings, well below its own five-year average of 8.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 3.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.16**. A PEG of 0.16 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.3×**. Each dollar of revenue is priced at 0.3×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **EV / EBITDA: 5.6×**. Enterprise value is 5.6× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 50.1%** (5-yr avg 14.4%). Free cash flow equals 50.1% of the market value, above its five-year average of 14.4%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 25.3%**. The inverse of the P/E: 25.3% of the price is earned each year.

## Profitability
- **Gross margin: 59.0%**. Embecta Corp. keeps 59.0% of revenue after the direct cost of what it sells.
- **Operating margin: 21.9%**. 21.9% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 8.8%**. 8.8% of each dollar of sales reaches the bottom line.
- **Return on equity: -14.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 33.8%**. Return on all capital, debt included, is 33.8%: comfortably above what that capital costs.
- **Return on assets: 8.0%**. Each dollar of assets produces 8.0% of profit.

## Growth
- **Revenue growth (1 yr): -3.8%** (3-yr -1.5%/yr, 5-yr -0.1%/yr). Revenue fell 3.8% over the last year, against -0.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 20.9%** (3-yr -25.3%/yr, 5-yr -26.4%/yr). Earnings per share rose 20.9%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -22.3%/yr**. Free cash flow has compounded at -22.3% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Net debt / EBITDA: 4.4×**. It would take 4.4 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.69%** ($0.46 per share, trailing). Embecta Corp. yields 0.69%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 37%** (17% of free cash flow). 37% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 4**. 4 straight years of increases.

## Price and momentum
- **Total return (1 yr): -58.7%** (YTD -50.3%, 3-mo 71.6%). The shares are down 58.7% over twelve months including dividends.
- **From 52-week high: -62.7%** (109.4% above the low). Trading 63% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 75**. An RSI of 75 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.54** (volatility 80%). Beta of 0.54 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EMBC · Page: https://foliofundamentals.com/stocks/embc

Not investment advice.